# Signacor Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/signacor-therapeutics

- Industry: Biotechnology
- Headquarters: Belfast, UK
- Website: www.signacor.co.uk/
- Total disclosed funding: $0.3M
- Latest round: Seed (Mar 10, 2026)
- Investors on record: 1

## About

SignaCor Therapeutics, founded in 2024 by Chris Watson (CSO) and headquartered in Belfast, UK, is dedicated to developing advanced therapeutic solutions for hypertrophic cardiomyopathy (HCM). The company has successfully completed its first funding round, securing EUR 288000 in Seed funding from investor Zinc in March, 2026. This funding will enable the company to progress its clinical trial efforts. As of August 2026 company is led by Darach Neeson as a CEO.
SignaCor's primary product offering is Cardiaza, an innovative injectable therapy designed to treat symptomatic hypertrophic cardiomyopathy (HCM). This first-in-class therapeutic leverages DNA methylation to target multiple underlying mechanisms contributing to the disease, such as pathological fibrosis and cardiomyocyte hypertrophy. Cardiaza is specifically intended for patients suffering from symptomatic HCM, a prevalent genetic condition affecting approximately 1 in 500 adults worldwide. SignaCor primarily serves markets in the United Kingdom and Europe, with plans to expand into North America and other international markets as development progresses.
SignaCor operates within a business model that focuses on the development and commercialization of its flagship product, Cardiaza, targeting healthcare providers and institutions that treat cardiac patients. Revenue generation is anticipated through partnerships with medical facilities and potentially direct sales to hospitals and clinics specializing in cardiac care. Given the nature of the product, transactions are expected to occur via direct-to-consumer models and B2B agreements with healthcare institutions. The company is positioned to establish pricing plans based on the therapeutic benefits offered by Cardiaza, which addresses the underlying disease pathology of HCM. As a clinical-stage biotech firm, the monetization strategy will likely evolve following successful clinical trials and regulatory approvals, paving the way for market entry and revenue realization.
In March 2026, SignaCor Therapeutics raised EUR 288,000 in Seed funding from Zinc to advance the development of a novel therapy designed to repair heart damage and slow hypertrophic cardiomyopathy (HCM). The funding will support the company's Phase 2a clinical trial and regulatory activities, helping bring a new treatment option to patients with limited existing therapies, while also supporting future expansion beyond the UK and Europe into North America and other international markets.

## Funding rounds

- Seed, Mar 10, 2026, $0.3M — Zinc

## Investors

- Zinc (https://capitalatlas.ai/funds/zinc) — Seed